Radio-guided lymph node resection with prostate-specific membrane antigen in prostate cancer: Initial experience

Acknowledgments

None.

Statement of ethics

This study was approved by the ethics committee of Hospital Durand. All patients agreed to participate in the study and remain anonymous as agreed. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Conflict of interest statement

None.

Funding source

None.

Author contributions

CCG: Data curation, writing, methodology;

RM, WDB, CG: Supervision;

LGB, MGF, BSN, CVC, LPS: Data curation;

SR: Methodology;

DB: Supervision, data analysis, final draft writing, methodology.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 2021; 79(2):243-262.

[2] Schilham MGM, Somford DM, Küsters-Vandevelde HVN, et al. Prostate-specific membrane antigen-targeted radioguided pelvic lymph node dissection in newly diagnosed prostate cancer patients with a suspicion of locoregional lymph node metastases: The DETECT trial. J Nucl Med 2024; 65(3):423-429.

[3] Kimura S, Abufaraj M, Janisch F, et al. Performance of [⁶⁸Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2020; 23(1):1-10.

[4] Jiao J, Zhang J, Wen W, Qin W, Chen X. Prostate-specific membrane antigen-targeted surgery in prostate cancer: Accurate identification, real-time diagnosis, and precise resection. Theranostics 2024; 14(7):2736-2756.

[5] Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with ¹⁸F-DCFPyL in prostate cancer patients (OSPREY). J Urol 2021; 206(1):52-61.

[6] Mix M, Schultze-Seemann W, von Büren M, et al. ^99mTc-labelled PSMA ligand for radio-guided surgery in nodal metastatic prostate cancer: Proof of principle. EJNMMI Res 2021; 11(1):22.

[7] Maurer T, Weirich G, Schottelius M, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol 2015; 68(3):530-534.

[8] Lunger L, Steinhelfer L, Korn P, et al. Prostate-specific membrane antigen-radioguided surgery facilitates pelvic lymph node dissection during radical prostatectomy for the treatment of locally advanced prostate cancer with regional lymph node metastases. Eur Urol Oncol 2023; 6(1):95-98.

[9] Jilg CA, Reichel K, Stoykow C, et al. Results from extended lymphadenectomies with [¹¹¹In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer. EJNMMI Res 2020; 10(1):17.

[10] Gandaglia G, Mazzone E, Stabile A, et al. Prostate-specific membrane antigen radioguided surgery to detect nodal metastases in primary prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: Results of a planned interim analysis of a prospective phase 2 study. Eur Urol 2022; 82(4):411-418.